Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT06990529
- Locations
- 🇺🇸
National Institute of Health, Bethesda, Maryland, United States
Leniolisib for Immune Dysregulation in CVID
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT06897358
- Locations
- 🇺🇸
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
Leniolisib for Immune Dysregulation in PIDs
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT06549114
- Locations
- 🇺🇸
National Institute of Health, Bethesda, Maryland, United States
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 3
- Registration Number
- NCT06249997
- Locations
- 🇯🇵
Tokyo Medical And Dental University Hospital, Tokyo, Bunkyo-ku, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Hiroshima City, Japan
A trial to test the effect of leniolisib in children from 1 to 6 years of age with APDS
- Conditions
- Activated Phosphoinositide 3-Kinase Delta Syndrome
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 4
- Registration Number
- 2022-502180-38-00
- Locations
- 🇪🇸
University Hospital Virgen Del Rocio S.L., Sevilla, Spain
🇵🇹Unidade Local De Saude De Coimbra E.P.E., Coimbra, Portugal
Study of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome)
- Conditions
- Activated Phosphoinositide 3-Kinase Delta Syndrome
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 6
- Registration Number
- 2024-515489-15-00
- Locations
- 🇫🇷
Hopital Necker Enfants Malades, Paris, France
Prevention of Acute Kidney Injury in Patients With NSTEMI
- Conditions
- Non-ST Elevation Myocardial Infarction (NSTEMI)
- Interventions
- Drug: conestat alfa or placebo
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 29
- Registration Number
- NCT04912141
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
🇨🇭Inselspital Bern, Bern, Switzerland
🇨🇭University Hospital Geneva, Geneva, Switzerland
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 38
- Registration Number
- NCT04530136
- Locations
- 🇺🇸
Virtua Marlton Hospital, Marlton, New Jersey, United States
🇺🇸Virtua Memorial Hospital, Mount Holly, New Jersey, United States
🇺🇸The Valley Hospital, Ridgewood, New Jersey, United States
Patient Registry to Evaluate the Real-world Safety of Ruconest®
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 152
- Registration Number
- NCT03697187
- Locations
- 🇺🇸
The US Hereditary Angioedema Association, Fairfax, Virginia, United States
Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLI
- Conditions
- Activated PI3Kdelta Syndrome (APDS); PASLI Disease
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 37
- Registration Number
- NCT02859727
- Locations
- 🇷🇺
Pharming Investigative Site, Moscow, Russian Federation